High-Shear Wet Granulation of Bovine Bile Extract and the Binder Viscosity Plateau at 25°C

Bovine bile extract pharma grade is a heterogeneous animal-derived material containing conjugated cholic and deoxycholic acids, residual phospholipids, and minor bilirubin-related pigments. It is not a single chemical entity, so tablet formulation must be designed around a manufacturer-specified total bile acid content, moisture, and TSE documentation under EMA/410/01 Rev. 3 and Ph. Eur. 5.2.8. High-shear wet granulation is selected for immediate-release choleretic tablets when the extract loading reaches 35–60 wt% of the core mass. In a representative 250 mg core containing 100 mg extract, povidone K30 is added as a 5% aqueous binder solution at a dry binder level of 3 wt%. The granulator is operated with an impeller speed of 300–500 rpm and a chopper speed of 1500–3000 rpm; endpoint is controlled by torque or power draw rather than fixed time because the extract becomes pasty when the binder volume exceeds the wet mass saturation point. The wet mass is milled through a 1.5 mm screen and dried in a fluid-bed dryer with inlet air at 55–65°C until loss on drying is held at 2.0–3.5%. Extragranular croscarmellose sodium at 3 wt%, microcrystalline cellulose at 20 wt%, magnesium stearate at 0.5 wt%, and talc at 1 wt% are added after dry screening; lubrication is limited to 2 min to avoid hydrophobic film formation. Compression on a rotary press at 12–18 kN produces a hardness range of 50–80 N and disintegration below 15 min under USP <701> or Ph. Eur. 2.9.1. Dissolution testing under USP <711> or Ph. Eur. 2.9.3 requires a medium selected after pH-solubility profiling, because unconjugated bile acid fractions can precipitate below pH 4.0; a product-specific Q value is established rather than a universal monograph limit. The dried tablet cores are film-coated with an HPMC-based system to 3 wt% weight gain for taste masking. The terminal product is an immediate-release oral tablet for choleretic or lipotropic use. Direct compression is generally avoided at extract loadings above 25 wt% because the cohesive fines raise the angle of repose above 40° and produce segregation in the feed frame.

Why Hard Capsule Filling Requires Moisture Control Below aw 0.35 Before Paddle Feeder Transfer?

Hard capsule filling with bovine bile extract at 40–50 wt% in size 0 HPMC capsules is controlled primarily by water activity rather than by total moisture alone. At aw 0.35 or below, the powder bed remains free-flowing and transfers through the paddle feeder into dosator tubes with minimal fill weight drift. Above aw 0.35, the hygroscopic extract begins to form interparticle liquid bridges, the angle of repose rises above 40°, and the dosator pins compact the wet powder instead of cutting a uniform plug. The representative blend contains microcrystalline cellulose 30 wt%, lactose monohydrate 20 wt%, sodium starch glycolate 2 wt%, colloidal silicon dioxide 1 wt%, and sodium stearyl fumarate 1 wt%. The pre-blend is dried in a vacuum oven at 40°C under reduced pressure until water activity is ≤0.35 or Karl Fischer moisture is ≤2.0% by USP <921> or Ph. Eur. 2.5.12. The dried blend is passed through a 0.8 mm screen and loaded directly into a dosator-type capsule filler. A representative fill weight of 300 mg delivers 120 mg extract per capsule, with uniformity of dosage units controlled under USP <905> or Ph. Eur. 2.9.40 and an acceptance value ≤15.0. HPMC capsules are preferred over gelatin because the extract contains residual phospholipids that can accelerate gelatin cross-linking when stored above 25°C/60% RH. The terminal product is a hard capsule for bile acid supplementation or digestive support. Sodium stearyl fumarate is used instead of magnesium stearate because the extract’s acidic fractions can de-lubricate the dosage form at extended mixing times.

Because the compendial test set changes across oral and injectable forms, the following matrix is applied during batch release.

Fluid-bed top-spray granulation of a 45 wt% bovine bile extract composition with lactose monohydrate 30 wt% and pregelatinized starch 15 wt% using a 5% povidone K30 solution sprayed at 8–12 g/min per 2.0 kg batch yields granules with D50 180–250 µm when the inlet air temperature is held at 60°C ± 5°C and the product temperature is kept at 32–36°C. The terminal unit is a single-dose sachet containing 1.0 g granules for reconstitution in 10 mL water; xanthan gum 0.3 wt% and sucralose 0.15 wt% are dry-mixed into the granule blend as suspending and taste-masking agents. The process boundary is the spray rate: below 8 g/min the bed dewets and generates fines below 75 µm that segregate in the holding hopper, while above 12 g/min binder accumulates around the nozzle and causes local defluidization. Loss on drying of the finished granules is held at ≤1.5% to prevent compaction and caking in high-density polyethylene stick packs during storage at 25°C/60% RH. Uniformity of mass is tested under USP <905> or Ph. Eur. 2.9.5 with an acceptance value ≤15.0; particle size is controlled by USP <786> or Ph. Eur. 2.9.38 sieve analysis. The terminal product is an oral granule for bile acid supplementation in patients who cannot swallow intact tablets or capsules; the reconstituted suspension must be administered immediately after shaking because the surface-active bile salts generate persistent foam.

Shifting From Oral Blend to Lyophilised Injectable Powder Replaces USP <905> With USP <788>

Parenteral use of bovine bile extract imposes a different control set from oral granulation. The extract is dissolved in Water for Injections at 20–25°C, and the solution is adjusted to pH 7.0–7.4 with dilute sodium hydroxide or phosphate buffer to keep conjugated bile salts ionized. The solution is prefiltered through a 0.45 µm polypropylene membrane and sterilized through a 0.22 µm PVDF membrane. Because bile salts are surface-active, the filter train is operated at a constant differential pressure below 0.8 bar to reduce micellar gel formation at the membrane surface. The filtered solution is filled into Type I glass vials and lyophilized: freezing to −40°C at 0.5°C/min, primary drying at −20°C shelf temperature and 100 µbar chamber pressure for 24 h, secondary drying at 20°C until Karl Fischer moisture is ≤1.0%. The dry cake is reconstituted with 0.9% NaCl or Water for Injections immediately before administration. Compendial controls shift to USP <788> or Ph. Eur. 2.9.19 for sub-visible particles: counts must not exceed 6000 per container at ≥10 µm and 600 per container at ≥25 µm for small-volume parenterals. Bacterial endotoxin limits are calculated under USP <85> or Ph. Eur. 2.6.14 using the default intravenous threshold of 5 EU/kg/h under Ph. Eur. 5.1.10, adjusted for maximum dosing rate. Elemental impurity limits follow ICH Q3D for the parenteral route. Because free bile acids are membrane-active surfactants, injectable development requires product-specific in vitro hemolysis testing; the critical micelle concentration of sodium deoxycholate in isotonic saline at 25°C is commonly reported in the 2–6 mM range, but the crude bovine extract contains phospholipids and other amphiphiles that shift this aggregation boundary. Published data for this specific configuration is limited, and no oral-grade safety inference is acceptable. TSE control follows EMA/410/01 Rev. 3 and Ph. Eur. 5.2.8. The terminal product is a sterile lyophilised powder for injection, intended for reconstitution under aseptic conditions and not for terminal steam sterilization.

When Enteric Coating Thickness Falls Below 7 mg/cm², Acid Uptake in the Stomach Triggers Premature Bile Acid Release

Delayed-release tablet cores containing bovine bile extract are coated with Eudragit L 30 D-55 aqueous dispersion plasticized with triethyl citrate at 20% w/w dry polymer and talc at 50% w/w dry polymer. The side-vented coating pan is operated with inlet air at 45°C, product temperature 28–32°C, and spray rate 3–6 g/min/kg pan load until the coating weight gain reaches 8–10 mg/cm²; curing at 40°C for 2 h completes film coalescence. If coating thickness falls below 7 mg/cm², acid-stage testing in 0.1 M HCl shows more than 10% release within 2 h, indicating penetration through edge defects or surface porosity. This premature release exposes the gastric mucosa to bile acid fractions and removes the intended duodenal delivery. The acid-stage test uses USP <711> or Ph. Eur. 2.9.3 with 750 mL of 0.1 M HCl for 2 h; the buffer stage continues in phosphate buffer pH 6.8, where the methacrylic acid copolymer dissolves and release is evaluated against a product-specific acceptance criterion. Tablet cores from the wet-granulated route are compressed at 12–18 kN and the uncoated surface roughness is held below 0.8 µm Ra to prevent coating pinholes. The terminal product is a duodenal-release choleretic tablet intended to reduce gastric irritation and deliver bile extract to the proximal small intestine.

Roller compaction of a 60 wt% bovine bile extract blend with microcrystalline cellulose 25 wt%, crospovidone 5 wt%, and magnesium stearate 0.5 wt% at roll force 6–8 kN/cm produces ribbons with a density of 0.8–1.2 g/cm³ when the pre-blend water activity is held below 0.35. Above 8 kN/cm the ribbons split along the axial plane and the subsequent milled granules contain excessive fines that increase tablet capping on a rotary press running at 30–60 rpm and 10–15 kN compression force. The dry granulation route is reserved for moisture-sensitive formulations in which wet granulation darkens the extract or shifts the conjugated bile acid profile; it removes the aqueous binder addition and reduces the drying thermal load. Ribbons are milled through a 1.0 mm screen, and the retained granule fraction between 125 µm and 500 µm is preferred for die filling. The final blend is compressed into tablets or filled into capsules. The dry-granulated material typically shows loss on drying ≤2.0%, angle of repose 35–40°, and acceptance value under USP <905> or Ph. Eur. 2.9.40 below 15. Terminal products are oral solid dosage forms for bile acid replacement in which the manufacturer must validate that dry granulation does not reduce bile acid assay through shear-induced segregation of phospholipid-rich fractions. Published data on the shear sensitivity of whole bovine bile extract is limited, so ribbon density and granule particle size must be correlated with assay and dissolution on a batch-specific basis.